We conducted a phase II multicenter trial to estimate the response and survival of @entity1 with newly diagnosed @entity1582 to high dose melphalan therapy followed by autologous peripheral blood stem cell transplantation. Eligible @entity1 who had undergone induction with @entity1891 , @entity632 and @entity619 (VAD) should have adequate cardiac, pulmonary and renal function ( @entity1011 <2 mg/dL). Melphalan at 200 mg/m2 was used as a conditioning regimen. Eighty @entity1 were enrolled from 13 centers. The median age of the @entity1 was 53 yr (range; 20 to 68 yr). The initial stage was IA/IIA/IIB/IIIA/IIIB in 3/8/1/54/14 @entity1 , respectively. @entity2262 , CRP and LDH were increased in 74, 42 and 34% of the @entity1 examined. Cytogenetic data were available in 30 @entity1 , and 6 @entity1 showed numeric or structural abnormalities. Two therapy-related mortalities occurred from @entity281 . Among the 78 evaluable @entity1 , CR/PR/MR/NC/PD were achieved in 48/26/2/1/1 @entity1 , respectively. After a median follow-up of 30 months, the median overall and event-free survivals were 66 months (95% CI: 20-112) and 24 months (95% CI: 18-29), respectively. This study verifies the efficacy and feasibility of high dose melphalan therapy with autologous stem cell transplantation in newly diagnosed @entity1582 .

High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for XXXX : a Korean Multicenter Study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['adriamycin'] @entity2262 :: ('567', 'Gene') :: ['Beta2-microglobulin'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']
